All In Biotech

Drug Trial Radar · NCT05362110

A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Sep 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 361 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

361

Actual

Start

May 16, 2022

Primary completion

Jun 5, 2023

Study completion Jun 5, 2023

Sponsor

Sponsor type
Industry
First posted
May 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HCP1803 in patients with essential hypertension

Conditions

  • Hypertension

Interventions

  • HCP1803-3Drug

    Take it once daily for 8 weeks orally.

  • RLD2002Drug

    Take it once daily for 8 weeks orally.

  • HPP2003-3Drug

    Placebo drug. Take it once daily for 8 weeks orally.

  • HPP2004Drug

    Placebo drug. Take it once daily for 8 weeks orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in sitting systolic blood pressureTime frame: baseline, 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Donggguk University Ilsan Hospital

    Goyang-si, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.